Mixed pleomorphic lobular and apocrine carcinoma of the breast: A case report suggesting pathogenesis

Ishii, Akiko; Oishi, Takuma; Kakuda, Yuko; Yasui, Haruna; Kawata, Takuya; Muramatsu, Koji; Takahashi, Kaoru; Sugino, Takashi

doi:10.1111/pin.12781

Cited by 2 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using modern criteria, these cases would be classified as pleomorphic LCIS (pLCIS) [27]. A recently reported single case of GCDFP-15-positive pleomorphic LCIS with accompanying invasive apocrine carcinoma led Ishii et al to postulate a pathogenetic link between the two entities, both of which were triple negative [28]. In a series of 13 cases of apocrine pLCIS reported by Chen et al, the majority of patients were postmenopausal [29].…”

Section: Apocrine Lobular Carcinoma In Situmentioning

confidence: 99%

Apocrine lesions of the breast

2021

View full text Add to dashboard Cite

Apocrine change is recognised in benign, atypical and malignant lesions of the breast. Apocrine metaplasia, a frequent finding in the breast of women over the age of 25 years, is most commonly seen in benign cysts with a simple or papillary configuration. Apocrine change is also recognised in other benign lesions including sclerosing adenosis, now known as apocrine adenosis. Apocrine atypia usually refers to cytological atypia in which there is at least threefold variation in nuclear size but architectural atypia may also occur. The distinction between atypical apocrine hyperplasia and non-high-grade apocrine ductal carcinoma in situ may be difficult due to the relative rarity of these entities and the lack of validated diagnostic criteria. Lobular carcinoma in situ (LCIS) with apocrine change is considered to be a variant of pleomorphic LCIS. An apocrine variant of encapsulated papillary carcinoma is also recognised. Apocrine change is described in invasive carcinoma, including no special type, lobular, micropapillary and mucinous variants. The recent WHO 2019 update recognises ‘carcinoma with apocrine differentiation’ as a special type breast carcinoma based on the presence of apocrine morphology in at least 90% of the tumour. Tumours with apocrine morphology are usually but not always hormone receptor negative. Human epidermal growth factor receptor 2 (HER-2) status is variable. Molecular studies have identified breast tumours with apocrine features and high expression of androgen receptor mRNA including ‘luminal androgen receptor tumours’ and ‘molecular apocrine tumours’. The term ‘pure apocrine carcinoma’ has been proposed to describe an invasive carcinoma with apocrine morphology that is oestrogen and progesterone receptor negative and androgen receptor positive. HER-2 status may be positive or negative. This article reviews the pathology of benign, atypical and malignant apocrine lesions of the breast, with emphasis on diagnostic criteria including an approach to evaluation of apocrine lesions on needle core biopsy, and recent advances in our understanding of invasive apocrine carcinoma.

show abstract

Section: Apocrine Lobular Carcinoma In Situmentioning

confidence: 99%

Apocrine lesions of the breast

2021

View full text Add to dashboard Cite

show abstract

Apocrine Variant of Pleomorphic Lobular Carcinoma In Situ

Zhong

Solomon²,

Cheng³

et al. 2020

American Journal of Surgical Pathology

View full text Add to dashboard Cite

To date, the apocrine variant of lobular carcinoma in situ (AP-LCIS) has been cursorily described as a subtype of lobular carcinoma in situ (LCIS). We retrospectively reviewed 34 cases of AP-LCIS (including 23 associated with invasive lobular carcinoma) to fully characterize it. AP-LCIS typically presented with screen-detected calcifications in older women (mean age: 65 y) and was characterized by distended terminal duct lobular units with relatively large “pleomorphic” cells, central necrosis, and calcifications. AP-LCIS cells exhibited abundant eosinophilic occasionally granular cytoplasm, hyperchromatic nuclei, and prominent nucleoli. Synchronous classic and/or florid LCIS was identified in 24/34 (70%) AP-LCIS, and in 9/11 (82%) pure AP-LCIS. Most (68%) cases of AP-LCIS were estrogen receptor–positive (50% strongly), 35% were progesterone receptor–positive, 26% were human epidermal growth factor 2–positive, 18% demonstrated high-proliferation rate (Ki67: >15%), and 90% were androgen receptor–positive. Aurora kinase A, immunoreactive in 38% of AP-LCIS cases, was not significantly associated with recurrence, development of invasion, or nodal positivity (P>0.05). Compared with conventional (nonapocrine) pleomorphic lobular carcinoma in situ (P-LCIS), aurora kinase A was expressed in a significantly greater proportion of P-LCIS (100%). AP-LCIS and P-LCIS did not otherwise differ in clinicopathologic features. Next-generation sequencing utilizing the Oncomine Comprehensive Panel v2, performed on 27 AP-LCIS cases, showed no specific molecular findings. In a mean follow-up of 57 months, 2 (of 11, 18%) pure AP-LCIS cases recurred (2 both in situ and invasive) and none metastasized or proved fatal. AP-LCIS should be regarded as another high-grade LCIS similar to P-LCIS in many respects, and pending additional studies should be managed similarly.

show abstract

Mixed pleomorphic lobular and apocrine carcinoma of the breast: A case report suggesting pathogenesis

Cited by 2 publications

References 19 publications

Apocrine lesions of the breast

Apocrine lesions of the breast

Apocrine Variant of Pleomorphic Lobular Carcinoma In Situ

Contact Info

Product

Resources

About